Latest news
Long-term outcomes with lorlatinib vs. crizotinib in ALK-positive NSCLC: Insights from the CROWN study: Written recap - managedhealthcareexecutive.commanagedhealthcareexecutive.com · Wed, 05 Aug 2026 23:52:19 GMTNuvation Bio will present IBTROZI data across lung cancer subgroups - Stock TitanStock Titan · Tue, 04 Aug 2026 12:00:00 GMTFDA approves GSK's Jideytro for previously treated ROS1-positive NSCLC, the company's first lung cancer clearance - OncodailyOncodaily · Wed, 29 Jul 2026 11:32:06 GMTELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC - The ASCO PostThe ASCO Post · Tue, 28 Jul 2026 14:29:40 GMTAdjuvant Ensartinib Improves DFS in Resected ALK-Positive NSCLC - CancerNetworkCancerNetwork · Mon, 27 Jul 2026 14:38:02 GMTJideytro Approved for Previously Treated ROS1-Positive NSCLC - Clinical Oncology NewsClinical Oncology News · Mon, 27 Jul 2026 07:00:00 GMT